Oncology · GlioblastomaTrial Updateclinicalmid-term

Phase I Trial of Peposertib with Radiation and Temozolomide in Glioblastoma

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/1/2026, 12:30:39 AM

Assessment confidence: 65% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing Phase I trial of Peposertib in combination with radiation and temozolomide represents a significant advancement in the treatment landscape for glioblastoma. If successful, it could redefine treatment protocols and enhance competitive positioning against existing therapies. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 23 ranked evidence items (10 high-relevance).

Strategic Assessment

The strongest clinical anchor is Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma (ClinicalTrials.gov), entity match (temozolomide). In Oncology · Glioblastoma, 4 regulatory and 4 competitive items passed relevance filtering for Piposertib. Successful trial outcomes could lead to increased market share for Peposertib and its combination therapy, potentially impacting revenue streams in the oncology sector.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC (Humanexa Signals) — sponsor/company relevance (pfizer). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study. If successful, this combination could enhance treatment options in a competitive glioblastoma market, particularly against existing therapies.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Moderate corpus alignment. The trial's results will influence future regulatory submissions and approvals, particularly in establishing new treatment guidelines for glioblastoma.

Key Risks

Elevated medium regulatory exposure for Piposertib could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful trial outcomes could lead to increased market share for Peposertib and its combination therapy, potentially impacting revenue streams in the oncology sector.
Upside for Piposertib may improve if Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Piposertib may improve if Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Piposertib may improve if Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for efficacy and safety data, as well as any subsequent trials or partnerships that may arise from this study.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma
ClinicalTrials.govhigh relevance
Entity match (temozolomide)
FDA document
View source
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
ClinicalTrials.govhigh relevance
Entity match (m d anderson cancer center)
FDA document
View source
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govhigh relevance
Entity match (m d anderson cancer center)
FDA document
View source
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Bristol-Myers Squibb Evaluates Pumitamig vs Pembrolizumab in NSCLC Trial
Humanexa Signalsmedium relevance
Moderate corpus alignment
Phase I/II Trial of Lentiviral Gene Transfer for XSCID in Children Over Two Years
Humanexa Signalsmedium relevance
Moderate corpus alignment

Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Burden of HPV-associated cancers in Peruvian men: Evidence from national health data.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Piposertib
Temozolomide
M.D. Anderson Cancer Center
National Cancer Institute

Commercial impact

medium

Successful trial outcomes could lead to increased market share for Peposertib and its combination therapy, potentially impacting revenue streams in the oncology sector.

Regulatory impact

medium

The trial's results will influence future regulatory submissions and approvals, particularly in establishing new treatment guidelines for glioblastoma.

What to watch

Monitor trial results for efficacy and safety data, as well as any subsequent trials or partnerships that may arise from this study.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.